Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1046

1.

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.

Pataer A, Shao R, Correa AM, Behrens C, Roth JA, Vaporciyan AA, Wistuba II, Swisher SG.

Cancer Med. 2018 Apr 19. doi: 10.1002/cam4.1505. [Epub ahead of print]

2.

Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients.

Sepesi B, Ye Y, Mitchell KG, Zhang L, Gu J, Ji L, Antonoff MB, Hofstetter WL, Rice DC, Mehran RJ, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Wu X.

J Thorac Cardiovasc Surg. 2018 Jun;155(6):2635-2645.e15. doi: 10.1016/j.jtcvs.2018.02.015. Epub 2018 Feb 15.

PMID:
29548588
3.

Clinicoradiographic Predictors of Aggressive Biology in Lung Cancer with Ground Glass Components.

Nelson DB, Godoy MC, Benveniste MF, Shewale JB, Spicer JD, Mitchell KG, Hofstetter WL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Antonoff MB.

Ann Thorac Surg. 2018 Mar 10. pii: S0003-4975(18)30332-1. doi: 10.1016/j.athoracsur.2018.02.020. [Epub ahead of print]

PMID:
29534957
4.

Enhanced Recovery Decreases Pulmonary and Cardiac Complications Following Thoracotomy for Lung Cancer.

Van Haren RM, Mehran RJ, Correa AM, Antonoff MB, Baker CM, Woodard TC, Hofstetter WL, Mena GE, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC.

Ann Thorac Surg. 2018 Mar 9. pii: S0003-4975(18)30318-7. doi: 10.1016/j.athoracsur.2018.01.088. [Epub ahead of print]

PMID:
29530770
5.

Overuse of antimicrobial prophylaxis in low-risk patients undergoing transurethral resection of the prostate.

Bausch K, Roth JA, Seifert HH, Widmer AF.

Swiss Med Wkly. 2018 Feb 23;148:w14594. doi: 10.4414/smw.2018.14594. eCollection 2018 Feb 23.

6.

Comparison of outcomes between muscle-sparing thoracotomy and video-assisted thoracic surgery in patients with cT1 N0 M0 lung cancer.

Mehran RJ, Martin LW, Roth JA.

J Thorac Cardiovasc Surg. 2018 Mar;155(3):1307. doi: 10.1016/j.jtcvs.2017.10.039. No abstract available.

PMID:
29452469
7.

Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer.

Shewale JB, Nelson DB, Rice DC, Sepesi B, Hofstetter WL, Mehran RJ, Vaporciyan AA, Walsh GL, Swisher SG, Roth JA, Antonoff MB.

Ann Thorac Surg. 2018 Jun;105(6):1671-1677. doi: 10.1016/j.athoracsur.2018.01.031. Epub 2018 Feb 9.

PMID:
29432718
8.

Defect Rates in Touchless Versus Mechanical Hand Hygiene Dispensers.

Roth JA, Batzer B, Hug BL, Widmer AF.

Infect Control Hosp Epidemiol. 2018 Mar;39(3):359-360. doi: 10.1017/ice.2017.306. Epub 2018 Jan 24. No abstract available.

PMID:
29363435
9.

TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models.

Meraz IM, Majidi M, Cao X, Lin H, Li L, Wang J, Baladandayuthapani V, Rice D, Sepesi B, Ji L, Roth JA.

Cancer Immunol Res. 2018 Feb;6(2):163-177. doi: 10.1158/2326-6066.CIR-17-0273. Epub 2018 Jan 16.

PMID:
29339375
10.

Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy.

Yan X, Wang L, Zhang R, Pu X, Wu S, Yu L, Meraz IM, Zhang X, Wang JF, Gibbons DL, Mehran RJ, Swisher SG, Roth JA, Fang B.

Oncoimmunology. 2017 Oct 31;7(1):e1376156. doi: 10.1080/2162402X.2017.1376156. eCollection 2017.

PMID:
29296537
11.

TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC).

Cao X, Zhao Y, Wang J, Dai B, Gentile E, Lin J, Pu X, Ji L, Wu S, Meraz I, Majidi M, Roth JA.

Oncotarget. 2017 Nov 21;8(64):107621-107629. doi: 10.18632/oncotarget.22581. eCollection 2017 Dec 8.

12.

Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities.

Huang X, Cao M, Wu S, Wang L, Hu J, Mehran RJ, Roth JA, Swisher SG, Wang RY, Kantarjian HM, Andreeff M, Sun X, Fang B.

Oncotarget. 2017 Nov 1;8(60):102150-102160. doi: 10.18632/oncotarget.22235. eCollection 2017 Nov 24.

13.

Direct Costs of a Contact Isolation Day: A Prospective Cost Analysis at a Swiss University Hospital.

Roth JA, Hornung-Winter C, Radicke I, Hug BL, Biedert M, Abshagen C, Battegay M, Widmer AF.

Infect Control Hosp Epidemiol. 2018 Jan;39(1):101-103. doi: 10.1017/ice.2017.258. Epub 2017 Dec 18.

PMID:
29249218
14.

Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial.

Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA.

Br J Cancer. 2018 Feb 6;118(3):331-337. doi: 10.1038/bjc.2017.423. Epub 2017 Dec 12.

PMID:
29235564
15.

Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial.

Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA.

Target Oncol. 2018 Feb;13(1):99-106. doi: 10.1007/s11523-017-0540-3.

PMID:
29218623
16.

Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.

Nelson DB, Rice DC, Niu J, Atay SM, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Tsao AS, Gomez DR, Giordano SH, Mehran RJ, Sepesi B.

Eur J Cardiothorac Surg. 2018 May 1;53(5):960-966. doi: 10.1093/ejcts/ezx427.

PMID:
29211849
17.

Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.

Wang JF, Pu X, Zhang X, Chen K, Xi Y, Wang J, Mao X, Zhang J, Heymach JV, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Meng QH, Shaw KR, Eterovic AK, Fang B.

Cancer. 2018 Mar 1;124(5):1061-1069. doi: 10.1002/cncr.31152. Epub 2017 Nov 27.

PMID:
29178133
18.

Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.

Shen J, Ye Y, Chang DW, Huang M, Heymach JV, Roth JA, Wu X, Zhao H.

Lung Cancer. 2017 Dec;114:70-78. doi: 10.1016/j.lungcan.2017.10.018. Epub 2017 Nov 2.

PMID:
29173770
19.

Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel.

Atay SM, Correa AM, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh G, Antonoff MB.

Ann Thorac Surg. 2017 Dec;104(6):1821-1828. doi: 10.1016/j.athoracsur.2017.05.021. Epub 2017 Oct 5.

PMID:
28987393
20.

Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1.

Zhang L, Lin J, Ye Y, Oba T, Gentile E, Lian J, Wang J, Zhao Y, Gu J, Wistuba II, Roth JA, Ji L, Wu X.

Clin Pharmacol Ther. 2017 Sep 10. doi: 10.1002/cpt.870. [Epub ahead of print]

PMID:
28891208
21.

A miR-SNP biomarker linked to an increased lung cancer survival by miRNA-mediated down-regulation of FZD4 expression and Wnt signaling.

Lin J, Zandi R, Shao R, Gu J, Ye Y, Wang J, Zhao Y, Pertsemlidis A, Wistuba II, Wu X, Roth JA, Ji L.

Sci Rep. 2017 Aug 22;7(1):9029. doi: 10.1038/s41598-017-09604-4.

22.

Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.

Nelson DB, Rice DC, Niu J, Atay S, Vaporciyan AA, Antonoff M, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Tsao A, Gomez D, Giordano SH, Mehran R, Sepesi B.

J Clin Oncol. 2017 Oct 10;35(29):3354-3362. doi: 10.1200/JCO.2017.73.8401. Epub 2017 Aug 17.

PMID:
28817374
23.

Value of the Pitt Bacteraemia Score to predict short-term mortality in Staphylococcus aureus bloodstream infection: a validation study.

Roth JA, Tschudin-Sutter S, Dangel M, Frei R, Battegay M, Widmer AF.

Swiss Med Wkly. 2017 Aug 14;147:w14482. doi: 10.4414/smw.2017.14482. eCollection 2017 Aug 14.

24.

Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.

Gentile E, Oba T, Lin J, Shao R, Meng F, Cao X, Lin HY, Mourad M, Pataer A, Baladandayuthapani V, Cai D, Roth JA, Ji L.

Oncotarget. 2017 Jul 18;8(29):48222-48239. doi: 10.18632/oncotarget.18421.

25.

MELD score as a predictor of mortality, length of hospital stay, and disease burden: A single-center retrospective study in 39,323 inpatients.

Roth JA, Chrobak C, Sch├Ądelin S, Hug BL.

Medicine (Baltimore). 2017 Jun;96(24):e7155. doi: 10.1097/MD.0000000000007155.

26.

The effect of manganese exposure in Atp13a2-deficient mice.

Fleming SM, Santiago NA, Mullin EJ, Pamphile S, Karkare S, Lemkuhl A, Ekhator OR, Linn SC, Holden JG, Aga DS, Roth JA, Liou B, Sun Y, Shull GE, Schultheis PJ.

Neurotoxicology. 2018 Jan;64:256-266. doi: 10.1016/j.neuro.2017.06.005. Epub 2017 Jun 6.

PMID:
28595912
27.

Comparison of humoral and T-cell-mediated immune responses to a single dose of Bovela® live double deleted BVDV vaccine or to a field BVDV strain.

Platt R, Kesl L, Guidarini C, Wang C, Roth JA.

Vet Immunol Immunopathol. 2017 May;187:20-27. doi: 10.1016/j.vetimm.2017.03.003. Epub 2017 Mar 19.

28.

MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk.

Zhang L, Ye Y, Tu H, Hildebrandt MA, Zhao L, Heymach JV, Roth JA, Wu X.

Ann Oncol. 2017 May 1;28(5):1124-1129. doi: 10.1093/annonc/mdx046.

29.

The Model for End-stage Liver Disease (MELD) as a predictor of short-term mortality in Staphylococcus aureus bloodstream infection: A single-centre observational study.

Roth JA, Widmer AF, Tschudin-Sutter S, Dangel M, Frei R, Battegay M, Hug BL.

PLoS One. 2017 Apr 17;12(4):e0175669. doi: 10.1371/journal.pone.0175669. eCollection 2017.

30.

Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility.

Zhang Y, Zhang L, Li R, Chang DW, Ye Y, Minna JD, Roth JA, Han B, Wu X.

Ann Oncol. 2017 Jul 1;28(7):1625-1630. doi: 10.1093/annonc/mdx161.

PMID:
28383694
31.

Polytetrafluoroethylene or Acellular Dermal Matrix for Diaphragmatic Reconstruction?

Bassuner JK, Rice DC, Antonoff MB, Correa AM, Walsh GL, Vaporciyan AA, Garg N, Sepesi B, Swisher SG, Hofstetter WL, Roth JA, Mehran RJ.

Ann Thorac Surg. 2017 Jun;103(6):1710-1714. doi: 10.1016/j.athoracsur.2017.01.006. Epub 2017 Mar 31.

PMID:
28366460
32.

7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.

Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY.

Cancer. 2017 Aug 15;123(16):3031-3039. doi: 10.1002/cncr.30693. Epub 2017 Mar 27.

PMID:
28346656
33.

Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.

Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, Heymach JV, Swisher SG, Bernatchez C, Alatrash G, Hanash S, Molldrem JJ.

Cancer Immunol Res. 2017 Apr;5(4):319-329. doi: 10.1158/2326-6066.CIR-16-0141. Epub 2017 Mar 2.

34.

Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.

Roth JA, Goulart BH, Ravelo A, Kolkey H, Ramsey SD.

Oncologist. 2017 Mar;22(3):304-310. doi: 10.1634/theoncologist.2016-0253. Epub 2017 Feb 27.

35.

A qualitative study exploring why individuals opt out of lung cancer screening.

Carter-Harris L, Brandzel S, Wernli KJ, Roth JA, Buist DSM.

Fam Pract. 2017 Apr 1;34(2):239-244. doi: 10.1093/fampra/cmw146.

PMID:
28122849
36.

TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin.

Xiaobo C, Majidi M, Feng M, Shao R, Wang J, Zhao Y, Baladandayuthapani V, Song J, Fang B, Ji L, Mehran R, Roth JA.

Sci Rep. 2016 Nov 15;6:35741. doi: 10.1038/srep35741.

37.

Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan.

Wu X, Wen CP, Ye Y, Tsai M, Wen C, Roth JA, Pu X, Chow WH, Huff C, Cunningham S, Huang M, Wu S, Tsao CK, Gu J, Lippman SM.

Sci Rep. 2016 Nov 2;6:36482. doi: 10.1038/srep36482.

38.

The Influence of Reconstructive Technique on Perioperative Pulmonary and Infectious Outcomes Following Chest Wall Resection.

Spicer JD, Shewale JB, Antonoff MB, Correa AM, Hofstetter WB, Rice DC, Vaporciyan AA, Mehran RJ, Walsh GL, Roth JA, Swisher SG, Sepesi B.

Ann Thorac Surg. 2016 Nov;102(5):1653-1659. doi: 10.1016/j.athoracsur.2016.05.072. Epub 2016 Aug 12.

PMID:
27526650
39.

Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.

Hart R, Veenstra DL, Boudreau DM, Roth JA.

Am J Med. 2017 Feb;130(2):222-228. doi: 10.1016/j.amjmed.2016.08.017. Epub 2016 Sep 2.

40.

Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response.

Pickering BS, Hardham JM, Smith G, Weingartl ET, Dominowski PJ, Foss DL, Mwangi D, Broder CC, Roth JA, Weingartl HM.

Vaccine. 2016 Sep 14;34(40):4777-86. doi: 10.1016/j.vaccine.2016.08.028. Epub 2016 Aug 17.

PMID:
27544586
41.

Quality of life after video-assisted surgery for lung cancer.

Mehran RJ, Roth JA.

Lancet Oncol. 2016 Aug;17(8):e315-e316. doi: 10.1016/S1470-2045(16)30229-7. No abstract available.

PMID:
27511151
42.

Gene Therapy for Lung Cancer.

Lara-Guerra H, Roth JA.

Crit Rev Oncog. 2016;21(1-2):115-24. doi: 10.1615/CritRevOncog.2016016084. Review.

43.

MicroRNA-mediated target mRNA cleavage and 3'-uridylation in human cells.

Xu K, Lin J, Zandi R, Roth JA, Ji L.

Sci Rep. 2016 Jul 21;6:30242. doi: 10.1038/srep30242.

44.

MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer.

Lin J, Xu K, Wei J, Heimberger AB, Roth JA, Ji L.

J Gene Ther. 2016 Feb;2(1). pii: 6. Epub 2016 Feb 13.

45.

Neuraminidase inhibiting antibody responses in pigs differ between influenza A virus N2 lineages and by vaccine type.

Sandbulte MR, Gauger PC, Kitikoon P, Chen H, Perez DR, Roth JA, Vincent AL.

Vaccine. 2016 Jul 19;34(33):3773-9. doi: 10.1016/j.vaccine.2016.06.001. Epub 2016 Jun 17.

PMID:
27325350
46.

Carbaryl-induced ototoxicity in rat postnatal cochlear organotypic cultures.

Prakash Krishnan Muthaiah V, Ding D, Salvi R, Roth JA.

Environ Toxicol. 2017 Mar;32(3):956-969. doi: 10.1002/tox.22296. Epub 2016 Jun 14.

PMID:
27296064
47.

Impact of oral meloxicam and long-distance transport on cell-mediated and humoral immune responses in feedlot steers receiving modified live BVDV booster vaccination on arrival.

Van Engen NK, Platt R, Roth JA, Stock ML, Engelken T, Vann RC, Wulf LW, Busby WD, Wang C, Kalkwarf EM, Coetzee JF.

Vet Immunol Immunopathol. 2016 Jul;175:42-50. doi: 10.1016/j.vetimm.2016.05.006. Epub 2016 May 12.

PMID:
27269791
48.

Effect of manganese and manganese plus noise on auditory function and cochlear structures.

Muthaiah VPK, Chen GD, Ding D, Salvi R, Roth JA.

Neurotoxicology. 2016 Jul;55:65-73. doi: 10.1016/j.neuro.2016.05.014. Epub 2016 May 24.

PMID:
27235191
49.

Different dietary patterns and reduction of lung cancer risk: A large case-control study in the U.S.

Tu H, Heymach JV, Wen CP, Ye Y, Pierzynski JA, Roth JA, Wu X.

Sci Rep. 2016 May 27;6:26760. doi: 10.1038/srep26760.

50.

Ototoxicity of Divalent Metals.

Roth JA, Salvi R.

Neurotox Res. 2016 Aug;30(2):268-82. doi: 10.1007/s12640-016-9627-3. Epub 2016 May 3. Review.

PMID:
27142062

Supplemental Content

Support Center